biostudies-literatureMendler JHNCI NIH HHS3109-18https://www.ebi.ac.uk/biostudies/studies/S-EPMC3732007biostudies-literatureUnknown30(25)<h4>Purpose</h4>To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures.<h4>Patients and methods</h4>Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays.<h4>Results</h4>RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated wiJournal of clinical oncology : official journal of the American Society of Clinical OncologyRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.PMC3732007CA129657CA101140U24 CA114725R21 CA129657CA16058CA114725CA33601CA31946U10 CA031946P30 CA016058CA140158U10 CA077658U10 CA101140CA77658U10 CA033601P50 CA140158Kolitz JERadmacher MDMendler JHWhitman SPMaharry KBecker HMoore JOSchwind SKhalife JWetzler MLarson RAMrozek KCarter THNicolet DMetzeler KHBloomfield CDCarroll AJKohlschmidt JPowell BLMarcucci GBaer MRCaligiuri MAfalseRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.<h4>Purpose</h4>To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures.<h4>Patients and methods</h4>Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays.<h4>Results</h4>RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated wi2012-01-01T00:00:00Z2012 Sep2026-05-29T15:44:38.214Z2019-03-27T01:13:59ZS-EPMC37320072275390210.1200/jco.2011.40.665210.1200/JCO.2011.40.6652